{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T20:44:58Z","timestamp":1787517898456,"version":"build-2736575974"},"reference-count":79,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:p>\n            The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF), dolutegravir (DTG)+FTC\/TAF, DTG\/lamivudine (3TC), and DTG\/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time to\n            <jats:italic>in vitro<\/jats:italic>\n            viral breakthrough (VB) and resistance barrier using simulated human drug exposures at either full or suboptimal treatment adherence to each regimen were compared.\n          <\/jats:p>","DOI":"10.1128\/aac.02038-21","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T13:00:26Z","timestamp":1649336426000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence\n            <i>In Vitro<\/i>"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-9487","authenticated-orcid":true,"given":"Rima K.","family":"Acosta","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"D\u2019Antoni","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mulato","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Yant","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L.","family":"White","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152611795589663"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020"},{"key":"e_1_3_2_4_2","unstructured":"World Health Organization (WHO). 2021. Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring: recommendations for a public health approach. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_5_2","unstructured":"U.S. Department of Health & Human Services (DHHS) AIDSInfo. 2019. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. DHHS Silver Spring MD."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_3_2_7_2","unstructured":"European AIDS Clinical Society (EACS). 2019. The EACS guidelines version 10. European AIDS Clinical Society Brussels Belgium."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70736-4"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61170-3"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000790"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Cahn P Madero JS Arribas JR Antinori A Ortiz R Clarke AE Hung CC Rockstroh JK Girard PM Sievers J Man CY Urbaityte R Brandon DJ Underwood M Pappa KA Smith KY Gartland M Aboud M van Wyk J Wynne B. 2022. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection. AIDS 36:39\u201348.","DOI":"10.1097\/QAD.0000000000003070"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky564"},{"key":"e_1_3_2_16_2","unstructured":"Workowski K Orkin C Sax P Hagins D Koenig E Stephens J Wohl A Lazzarin A Gupta S Huang H Acosta R Hindman J Brainard D Collins S Martin H. 2021. Four-year outcomes of B\/F\/TAF in treatment-na\u00efve adults. Poster 2268 HIV Medicine 22(SUPPL 2):32\u201333. 10.1111\/hiv.13131."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa202"},{"key":"e_1_3_2_18_2","unstructured":"Vanig T Marcelin AG Calvez V. Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by bictegravir. Poster PE13\/7."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104717"},{"key":"e_1_3_2_20_2","unstructured":"Braun P Wiesmann F Naeth G Knechten H Stoll M. 2020. Development of integrase inhibitor resistance under firstline treatment with bictegravir. Poster 125. http:\/\/www.hivglasgow.org\/wp-content\/uploads\/2020\/11\/P125_Braun.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.M18000026"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/426595"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/507549"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d8c2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2016.0071"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002562"},{"key":"e_1_3_2_28_2","volume-title":"BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use.","author":"Gilead Sciences Inc","year":"2021","unstructured":"Gilead Sciences Inc. 2021. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Gilead Sciences Inc, Foster City, CA."},{"key":"e_1_3_2_29_2","unstructured":"GlaxoSmithKline. 2019. DOVATO (dolutegravir and lamivudine) tablets for oral use. GlaxoSmithKline Research Triangle Park NC."},{"key":"e_1_3_2_30_2","unstructured":"GlaxoSmithKline. 2021. JULUCA (dolutegravir and rilpivirine) tablets for oral use. GlaxoSmithKline Research Triangle Park NC."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_3_2_32_2","unstructured":"European Medicines Agency (EMA). 2011. Assessment report: edurant. International non-proprietary name: rilpivirine. Procedure no. EMEA\/H\/C\/002264. European Medicines Agency Amsterdam the Netherlands."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_3_2_34_2","unstructured":"Custodio J West SK Lutz J Vu A Xiao D Collins S Das M Kearney BP Mathias A. 2017. Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection. Presentation. https:\/\/www.natap.org\/2017\/EACS\/EACS_47.htm."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169948"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01441-15"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.176-182.2004"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05599-11"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.875"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5653"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr291"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-10"},{"key":"e_1_3_2_43_2","unstructured":"Andreatta K Chang S Martin R Willkom M White KL. 2018. Integrase inhibitor resistance selections initiated with drug resistant HIV-1. Poster 546. https:\/\/www.natap.org\/2018\/CROI\/croi_134.htm."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040514"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004000"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06591-11"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-22"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0420-7"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3033"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3082"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky093"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.05.004"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262020-00001"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/427707"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067259"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay4919"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00611-20"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"e_1_3_2_65_2","unstructured":"Sax PE Althoff KN Eron JJ Radtchenko J Diaz-Cuervo H Mounzer K Ramgopal M Santiago S Elion RA. 2020. Impact of adherence on viral suppression with bictegravir- and dolutegravir (DTG)-containing triple therapy in clinical practice. Poster P029. https:\/\/www.natap.org\/2020\/GLASGOW\/GLASGOW_16.htm."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018761600"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001494"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy332"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy228"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1806554"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007096"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318249111"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)60646-5"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2992081"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2781"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01314.x"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27375"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02038-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02038-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:08:30Z","timestamp":1652792910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02038-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,17]]}},"alternative-id":["10.1128\/aac.02038-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02038-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"2021-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02038-21"}}